Invent targeted small molecule drugs
that are either first-in-class or second-generation
Selectively develop our drugs
to maximize their overall value
Perform a partnering strategy
in which we retain profit rights for drugs
through partner select early-stage programs
ABOUT US
BiSiChem is a leading biotech company that focused on the discovery and
development of innovative therapeutic drugs on immuno-oncology,
targeted therapy and neuro-degenerative diseases.
Our goals are Good lives, Better innovation and Best therapy.
HISTORY
LEADERSHIP
Our main focus is
“BiSiChem is a precision medicine company
developing a specific targeted therapy to treat cancer.”
VISION OF SCIENCE
Breakthrough discovery of therapeutics for unmet medical needs,
biomarker-based innovative, first-in-class or best-in-class candidates development
pipeline
develpment strategy
Research center
BiSiChem has a strength on preclinical candidate selection by target selection,
medicinal chemistry, biology and DMPK experties.
R&D Research Center. Pangyo
New Drug Research Center. Yongin
COLLABORATION
Lifex Biolabs Inc.
Asan Medical Center
KNU SCHOOL OF MEDICINE
InhaTarget Therapeutics
MediciBIO Co.,LTD.
contact
1006, C-dong, 357,
Guseong-ro, Giheung-gu,
Yongin-si, Gyeonggi-do,
Republic of Korea
Tel +82-31-698-3772
Fax +82-70-7610-2776
E-mail bsc@bisichem.com